Telix Pharmaceuticals Doses First Patient in Phase 3 Glioblastoma Trial

The IPAX BrIGHT study is evaluating a novel radiopharmaceutical therapy for recurrent brain cancer.

Apr. 15, 2026 at 2:20am

Got story updates? Submit your updates here. ›

A ghostly, translucent X-ray-style image showing the complex internal structure of a human brain tumor, glowing against a dark background and conveying the advanced medical technology being applied to this deadly form of cancer.A cutting-edge radiopharmaceutical therapy aims to target brain tumors from the inside out, offering new hope for glioblastoma patients with limited treatment options.Austin Today

Telix Pharmaceuticals Limited has dosed the first patient in its pivotal Phase 3 IPAX BrIGHT trial, which is assessing the safety and efficacy of the radiopharmaceutical therapy TLX101-Tx in combination with chemotherapy for patients with recurrent glioblastoma, an aggressive form of brain cancer. The global, multicenter study will enroll patients at first recurrence and marks the first radiopharmaceutical therapy to enter Phase 3 development for glioblastoma.

Why it matters

Glioblastoma is an extremely challenging cancer with limited treatment options, especially for patients whose disease recurs after initial therapy. TLX101-Tx offers a novel approach by targeting the LAT1 transporter to deliver radiation directly to the tumor, potentially improving outcomes compared to standard chemotherapy alone.

The details

The IPAX BrIGHT trial will compare the combination of TLX101-Tx and lomustine chemotherapy to lomustine alone. Earlier trials of TLX101-Tx have reported promising median overall survival results of 13 months from treatment initiation and 23 months from initial diagnosis. The study will also utilize Telix's investigational PET imaging agent TLX101-Px to select patients and assess metabolic tumor response.

  • The first patient was dosed at Austin Health in Melbourne, Australia on April 15, 2026.

The players

Telix Pharmaceuticals Limited

An Australian pharmaceutical company focused on developing radiopharmaceutical therapies, including TLX101-Tx for glioblastoma.

Professor Hui Gan

A physician at Austin Health in Melbourne, Australia who supervised the dosing of the first patient in the IPAX BrIGHT trial.

Got photos? Submit your photos here. ›

What’s next

The IPAX BrIGHT study has received regulatory approval in Australia, Austria, Belgium and the Netherlands, with approval being sought in additional jurisdictions.

The takeaway

The initiation of the pivotal IPAX BrIGHT trial represents an important milestone in the development of a novel radiopharmaceutical therapy that could potentially improve outcomes for glioblastoma patients with limited treatment options, especially those facing recurrent disease.